Drug details

Ngenla (somatrogon-ghla injection)

type of Growth Hormone Analogs

Ngenla (somatrogon-ghla) is a human growth hormone analog indicated for treatment of pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone.

This drug may have the following side effects:

• headache,
• vomiting,
• rash, and
• cough,
• anemia,
• fever,
• runny or stuffy nose,
• sore throat.
• abdominal pain,
• injection site reactions (pain, swelling, redness, itching, bleeding),
• hypothyroidism, 

The following drugs are related to Ngenla, either as a replacement or used together:

• Egrifta (tesamorelin injection)
• Egrifta SV (tesamorelin for injection)
• Genotropin (somatropin [rdna origin])
• Humatrope (somatropin rdna origin)
• Skytrofa (lonapegsomatropin-tcgd for injection)
• Norditropin (somatropin injection)
• Nutropin (somatropin (rdna origin) for inj)
• Nutropin AQ (somatropin (rdna origin))
• Nutropin Depot (somatropin (rdna origin) for inj)
• Omnitrope (somatropin [ rdna origin] injection)
• Saizen (somatropin injection)
• Serostim (somatropin (rdna origin))
• Sogroya (somapacitan-beco injection)
• Zomacton (somatropin (rdna origin) for injection)
• Zorbtive (somatropin rdna origin for injection)
• Tev-Tropin (somatropin, rdna origin, for injection)